autologous tumor lysate-pulsed DC-CIK cells

Autologous tumor lysate-pulsed DC-CIK cells is an adoptive cellular immunotherapy developed by Shenzhen Hornetcorn Bio-technology Company, LTD. The therapy involves the ex vivo generation and expansion of two distinct immune cell populations from a patient's peripheral blood: dendritic cells (DCs) and cytokine-induced killer (CIK) cells. The DCs are 'pulsed' or loaded with antigens derived from the patient's own tumor lysate, enabling them to present a broad spectrum of tumor-associated antigens to T cells. CIK cells are a heterogeneous population of effector lymphocytes (primarily CD3+CD56+ T cells) that possess potent, non-MHC-restricted cytotoxic activity. When co-cultured or administered together, the pulsed DCs enhance the specificity and activation of the CIK cells. This treatment is primarily investigated as an adjuvant therapy for patients with stage I-III colorectal cancer following surgery, chemotherapy, and radiotherapy to eliminate residual disease and prevent recurrence.

Other names

DC-CIK cellsautologous tumor lysate-pulsed dendritic cell-cytokine induced killer cellstumor lysate-pulsed DC-CIK